Remdesivir
Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors
Sold as Veklury
- Drug class
- Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors
- Availability
- See label
- Routes
- Intravenous
- Markets covered
- 3
- Products on record
- 3
Overview
Remdesivir is an active pharmaceutical ingredient in the Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors group (J05AB). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 1 | April 10, 2026 |
| EU European Union | EMA | 1 | January 6, 2026 |
| CA Canada | Health Canada | 1 | September 3, 2025 |
GBUnited Kingdom· MHRA
1 product
Uses
Veklury is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg): • with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment).
• who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19. 1).
How to take
EUEuropean Union· EMA
1 product
Uses
1)
How to take
CACanada· Health Canada
1 product
1 product on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [3].
Brands in Canada (1)
Drug interactions
Known interactions involving Remdesivir. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 296. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB119720036 · revised April 10, 2026
- [2]European Medicines Agency · EMEA/H/C/005622 · revised January 6, 2026
- [3]Health Canada (DPD) · 02502143 · revised September 3, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.